Assertio (ASRT)
(Delayed Data from NSDQ)
$1.11 USD
+0.04 (3.74%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $1.10 -0.01 (-0.90%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.11 USD
+0.04 (3.74%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $1.10 -0.01 (-0.90%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Zacks News
Factors that Make Molina Healthcare (MOH) an Attractive Bet Now
by Zacks Equity Research
Molina Healthcare (MOH) continues to ride on sustained top-line growth, well-performing Medicare and Medicaid businesses, and a strong cash position.
Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and ProPhase Labs, Inc. (PRPH) have performed compared to their sector so far this year.
Universal Health (UHS) Cuts Guidance, Falls 6.1%: What's Ahead?
by Zacks Equity Research
Universal Health's (UHS) acute care hospitals experience lower-than-expected patient volumes in the second quarter, inducing a decline in revenues and profits.
ASRT or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
JAZZ's Late-Stage Multiple Sclerosis Study on Nabiximols Fails
by Zacks Equity Research
JAZZ's phase III study evaluating nabiximols oromucosal spray for clinical measures of spasticity in multiple sclerosis patients fails to meet the primary endpoint.
HCA Healthcare (HCA) Boosts Cancer Portfolio With McKesson JV
by Zacks Equity Research
HCA Healthcare (HCA) inks a joint venture with McKesson to strengthen the cancer offerings suite of both partners. The move will offer HCA the chance to capitalize on the growing cancer therapeutics market.
Select Medical (SEM), Inova Health Form JV in Northern Virginia
by Zacks Equity Research
The JV between Select Medical (SEM) and Inova Health System is expected to own and operate a new 32-bed critical illness recovery facility.
Is Assertio (ASRT) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Encompass Health (EHC) Opens EHR-Backed Hospital in Florida
by Zacks Equity Research
Encompass Health (EHC) takes its U.S. inpatient rehabilitation hospital count to 150 with the opening of a hospital in Florida integrated with the sound EHR system of Oracle Cerner.
New Strong Buy Stocks for June 21st
by Zacks Equity Research
IMO, ASRT, LPX, EGLE, and CAL have been added to the Zacks Rank #1 (Strong Buy) List on June 21, 2022.
Assertio (ASRT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $2.78, moving +0.72% from the previous trading session.
Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Savara Inc. (SVRA) have performed compared to their sector so far this year.
Humana (HUM) to Offer Home Care Model to Virginia's MA Members
by Zacks Equity Research
Humana (HUM) expands the customer reach of its unit's value-based home care model to Virginia, with an aim to offer better in-home care services to the state's Medicare Advantage members.
ASRT vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Assertio (ASRT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed at $3.11 in the latest trading session, marking a +1.63% move from the prior day.
Best Momentum Stocks to Buy for June 10th
by Zacks Equity Research
ASRT, TTI and HCI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 10, 2022.
New Strong Buy Stocks for June 10th
by Zacks Equity Research
SBLK, SSB, HCI, ASRT, and TTI have been added to the Zacks Rank #1 (Strong Buy) List on June 10, 2022.
Anthem (ANTM) Up 27% in a Year: Can It Retain the Momentum?
by Zacks Equity Research
Anthem (ANTM) is well-poised for growth on sustained top-line improvement, membership increases in Government business and sturdy financial position.
Best Momentum Stocks to Buy for June 7th
by Zacks Equity Research
SBLK, ASRT and GOGL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 7, 2022.
New Strong Buy Stocks for June 7th
by Zacks Equity Research
SBLK, GOGL, LPX, ASRT, and CC have been added to the Zacks Rank #1 (Strong Buy) List on June 7, 2022.
Are Medical Stocks Lagging Assertio (ASRT) This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and UnitedHealth Group (UNH) have performed compared to their sector so far this year.
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Tenet Healthcare (THC) Unit Conifer Offers Services to Brookwood
by Zacks Equity Research
Tenet Healthcare's (THC) unit Conifer inks an agreement with Brookwood Baptist Health to deliver enhanced revenue cycle services to four of the remaining hospitals of the latter across Central Alabama.
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.
Assertio (ASRT) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of 122.22% and 10.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?